Hengrui Pharma's subsidiary HRS9531 injection has been approved to conduct clinical trials

AASTOCKS
2026.04.20 14:15

Hengrui Pharma (01276.HK) announced that its subsidiary Fujian Shengdi's HRS9531 injection has been approved by the National Medical Products Administration. This product will conduct clinical trials in overweight and obese adolescents. The marketing application for HRS9531 for long-term weight management in adults was accepted by the National Medical Products Administration in September 2025

Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2026 Longbridge｜Disclaimer